Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05626712 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

Study acronym: CREATE-1
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contact updatedv7
  2. Primary completion date: Jan 31, 2025 to Jan 31, 2027v6 Show 4 more changesShow less
    • Study completion date: Jan 31, 2026 to Jan 31, 2028
    • Eligibility criteria revised
    • Study description revised
    • Site contact updated
  3. Re-verified, no change to tracked fieldsv5
  4. Site contact updatedv4
  5. Trial status: Active, Not Recruiting to Recruiting
    • Start date: Feb 7, 2023 to Apr 7, 2023
    • Site details revised
    v3
  6. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Jan 1, 2023 to Feb 7, 2023
    • Site contact updated
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
Trial Details
NCT Number NCT05626712
Lead Sponsor Creative Medical Technology Holdings Inc
Conditions
(from sponsor)		 Type 1 Diabetes, Diabetes Mellitus, Type 1
Related terms Diabetes Mellitus, Type 1
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov